SCHEMBL1336769

SCHEMBL1336769

Cc1cccc(C)c1N(Cc1ccncc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.45
MAPK1 P28482 2/20 0.44
KMT2A Q03164 4/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 3/20 0.42
MEN1 O00255 3/20 0.42
TSHR P16473 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
LMNA P02545 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
MAPT P10636 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
BLM P54132 1/20 0.42
NFKB1 P19838 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925384 0.88 TRPM8 (0.57) TRPM8MAPK1KMT2AMEN1TSHR
SCHEMBL1336094 0.87 TSPO (0.46) KMT2AMEN1LMNAMAPTALDH1A1
Hydrochloric Acid SCHEMBL10993971 0.85 ALDH1A1 (0.48) TRPM8MAPK1KMT2AMEN1CYP3A4
SCHEMBL10995144 0.85 LTB4R2 (0.43) TRPM8MAPK1KMT2AMEN1TSHR
SCHEMBL1336864 0.80 TRPM8 (0.49) TRPM8KMT2ACYP2C9CYP2C19MEN1
SCHEMBL3062067 0.80 TRPM8 (0.50) TRPM8MAPK1KMT2AMEN1TSHR
SCHEMBL3057506 0.75 MAPT (0.48) TSHRLMNAMAPTHSD17B10MMP13
SCHEMBL1335585 0.75 MMP13 (0.50) KMT2ACYP2C19MEN1ALDH1A1MMP13
SCHEMBL1336855 0.74 TSHR (0.49) TRPM8KMT2ACYP2C9CYP2C19MEN1
SCHEMBL1336917 0.73 SMN1; SMN2 (0.46) TRPM8KMT2ACYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US claimed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP claimed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics GPR119, GLP1R, ADIPOR1 TRPM8 974/4885MAPK1 667/4885KMT2A 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.